193 related articles for article (PubMed ID: 36509750)
21. Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Moussa M; Papatsoris A; Abou Chakra M; Sryropoulou D; Dellis A
Expert Opin Pharmacother; 2020 Aug; 21(12):1431-1448. PubMed ID: 32469248
[TBL] [Abstract][Full Text] [Related]
22. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
[TBL] [Abstract][Full Text] [Related]
23. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Badrising S; van der Noort V; van Oort IM; van den Berg HP; Los M; Hamberg P; Coenen JL; van den Eertwegh AJ; de Jong IJ; Kerver ED; van Tinteren H; Bergman AM
Cancer; 2014 Apr; 120(7):968-75. PubMed ID: 24382803
[TBL] [Abstract][Full Text] [Related]
24. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Urol Oncol; 2017 Jun; 35(6):432-437. PubMed ID: 28188090
[TBL] [Abstract][Full Text] [Related]
25. Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
Izumi K; Mizokami A; Namiki M; Inoue S; Tanaka N; Yoshio Y; Ishibashi K; Kamiyama M; Kawai N; Enokida H; Shima T; Takahara S
BMC Cancer; 2017 Oct; 17(1):677. PubMed ID: 29017493
[TBL] [Abstract][Full Text] [Related]
26. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO
Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182
[TBL] [Abstract][Full Text] [Related]
27. Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment.
Mei Z; Yang T; Liu Y; Gao Y; Hou Z; Zhuang Q; He D; Zhang X; Tan Q; Zhu X; Qin Y; Chen X; Xu C; Bian C; Wang X; Wang C; Wu D; Huang S; Li Z
Cell Rep Med; 2022 May; 3(5):100608. PubMed ID: 35584629
[TBL] [Abstract][Full Text] [Related]
28. Differential adoption of castration-resistant prostate cancer treatment across facilities in a national healthcare system.
Caram MEV; Kumbier K; Burns J; Sparks JB; Tsao PA; Stensland KD; Washington SL; Hollenbeck BK; Shahinian V; Skolarus TA
Cancer Med; 2023 Mar; 12(6):6945-6955. PubMed ID: 36790037
[TBL] [Abstract][Full Text] [Related]
29. Targeting molecular resistance in castration-resistant prostate cancer.
Chandrasekar T; Yang JC; Gao AC; Evans CP
BMC Med; 2015 Sep; 13():206. PubMed ID: 26329698
[TBL] [Abstract][Full Text] [Related]
30. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan.
Okumura H; Inoue S; Naidoo S; Holmstrom S; Akaza H
Jpn J Clin Oncol; 2021 Aug; 51(8):1319-1329. PubMed ID: 34037235
[TBL] [Abstract][Full Text] [Related]
32. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?
Pereira-Salgado A; Kwan EM; Tran B; Gibbs P; De Bono J; IJzerman M
Eur Urol Focus; 2021 Jul; 7(4):752-763. PubMed ID: 32273196
[TBL] [Abstract][Full Text] [Related]
33. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
34. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domènech M; Rodríguez-Vida A; Carles J; Suárez C; Del Alba AG; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B
Int J Cancer; 2019 Oct; 145(7):1970-1981. PubMed ID: 30807643
[TBL] [Abstract][Full Text] [Related]
35. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis.
Mori K; Miura N; Mostafaei H; Quhal F; Sari Motlagh R; Pradere B; Kimura S; Kimura T; Egawa S; Briganti A; Karakiewicz PI; Shariat SF
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):539-548. PubMed ID: 32152435
[TBL] [Abstract][Full Text] [Related]
36. Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
Alibhai SMH; Breunis H; Feng G; Timilshina N; Hansen A; Warde P; Gregg R; Joshua A; Fleshner N; Tomlinson G; Emmenegger U
JAMA Netw Open; 2021 Jul; 4(7):e2114694. PubMed ID: 34213559
[TBL] [Abstract][Full Text] [Related]
37. Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
Suzuki H; Castellano D; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Jpn J Clin Oncol; 2021 Aug; 51(8):1287-1297. PubMed ID: 33738495
[TBL] [Abstract][Full Text] [Related]
38. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Predicts Prognosis for Castration Resistant Prostate Cancer Patients Underwent Enzalutamide.
Kumano Y; Hasegawa Y; Kawahara T; Yasui M; Miyoshi Y; Matsubara N; Uemura H
Biomed Res Int; 2019; 2019():9450838. PubMed ID: 30800682
[TBL] [Abstract][Full Text] [Related]
39. Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Kuppen MCP; Westgeest HM; van den Eertwegh AJM; van Moorselaar RJA; van Oort IM; Coenen JLLM; van den Bergh ACMF; Mehra N; Somford DM; Bergman AM; Ten Bokkel Huinink D; Fossion L; Geenen MM; Hendriks MP; van de Luijtgaarden ACM; Polee MB; Weijl NI; van de Wouw AJ; de Wit R; Uyl-de Groot CA; Gerritsen WR
Eur Urol Oncol; 2021 Aug; 4(4):618-627. PubMed ID: 31601523
[TBL] [Abstract][Full Text] [Related]
40. Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.
Papazoglou D; Wannesson L; Berthold D; Cathomas R; Gillessen S; Rothermundt C; Hasler L; Winterhalder R; Barth A; Mingrone W; Nussbaum CU; von Rohr L; von Burg P; Schmid M; Richner J; Baumann S; Kühne R; Stenner F; Rothschild SI
Clin Genitourin Cancer; 2017 Jun; 15(3):e315-e323. PubMed ID: 27450512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]